Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Assets: 2017-2024

Historic Non-Current Assets for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $59.2 million.

  • Crinetics Pharmaceuticals' Non-Current Assets rose 25.04% to $74.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.8 million, marking a year-over-year increase of 25.04%. This contributed to the annual value of $59.2 million for FY2024, which is 3.26% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Non-Current Assets of $59.2 million as of FY2024, which was down 3.26% from $61.2 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Non-Current Assets registered a high of $61.2 million during FY2023, and its lowest value of $6.0 million during FY2020.
  • For the 3-year period, Crinetics Pharmaceuticals' Non-Current Assets averaged around $42.5 million, with its median value being $59.2 million (2024).
  • Its Non-Current Assets has fluctuated over the past 5 years, first dropped by 15.42% in 2020, then surged by 775.29% in 2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Non-Current Assets (Yearly) stood at $6.0 million in 2020, then climbed by 5.75% to $6.3 million in 2021, then increased by 11.07% to $7.0 million in 2022, then spiked by 775.29% to $61.2 million in 2023, then declined by 3.26% to $59.2 million in 2024.